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Abstract
Background The oxaliplatin-based regimen FOLFOX is wide-
ly used to treat patients with advanced colorectal cancer (CRC).
However, dose-limiting toxicity after continuous oxaliplatin
administration can lead to peripheral neuropathy. Several
agents, including opioids, that have been employed to treat
oxaliplatin-induced peripheral neuropathy (OIPN) have been
examined in clinical settings regarding their protective and
therapeutic effects. However, the pharmacotherapy of these
agents has not yet been established. Therefore, we investigated
the efficacy and tolerability of oxycodone for OIPN and sub-
sequently with FOLFOX therapy in CRC patients.
Methods This was a single-center retrospective study of 64
CRC patients who underwent FOLFOX therapy at the Toho
University Sakura Medical Center (Sakura, Japan).
Controlled-release (CR) oxycodone was concomitantly ad-
ministered to 29 patients (OXY group), whereas the additional
35 patients (non-OXY group) were not given oxycodone
during the FOLFOX treatment course. The incidence and
severity of OIPN and the number of FOLFOX cycles were
measured and compared between the two groups. Neurolog-
ical toxicities were assessed according to the Common Ter-
minology Criteria for Advanced Events, version 3.0.
Results All study patients had OIPN. Most patients experi-
enced grade 1 or 2 sensory neuropathy. Grade 3 sensory
neuropathy was observed in two patients in the non-OXY
group. All patients in the OXY group completed the sched-
uled FOLFOX therapy, whereas FOLFOX therapy was
discontinued in ten patients in the non-OXY group due to
severe peripheral neuropathy. The median numbers of
FOLFOX cycles in the OXY and non-OXY groups were 13
(range, 6–46) and 7 (range, 2–18), respectively (P<0.05). The
median cumulative oxaliplatin doses were 1072.3 mg/m2
(range, 408.7–3385.3 mg/m2) in the OXY group and
483.0 mg/m2 (range 76.2–1414.1 mg/m2) in the non-OXY
group (P<0.05).
Conclusions Our findings indicate that CR oxycodone
might attenuate the severity of OIPN and extend the
use of FOLFOX therapy.
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cancer
Introduction
The occurrence of cancer therapy-related chronic pain has
become more frequent over the past few decades. This is
because cancer treatments such as surgery, chemotherapy,
hormonal therapy, and radiotherapy, among others, when used
individually and in combination, have potential side effects
that can lead to severe and persistent pain [1]. Chemotherapy-
induced peripheral neuropathy (CIPN), for example, has be-
come more prevalent as increased numbers of neurotoxic
agents have been introduced as treatment for different types
of cancer [2]. Dose reduction or discontinuation of these
chemotherapeutic agents might limit any potential curative
effects and ultimately reduce the chance of survival. There-
fore, CIPN is a common complication associated with several
classes of chemotherapeutic agents. These agents include
platinum-based compounds (cisplatin, carboplatin, and
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oxaliplatin), taxanes (paclitaxel and docetaxel), and vinca
alkaloids (vincristine and vinblastine). The symptoms of
CIPN mostly depend on the involved nerves. The most com-
mon symptoms are numbness, pain (shooting, stabbing, burn-
ing, tingling, or electric/shock-like pain), loss of feeling, im-
paired manual dexterity, balance problems, and decreased
or absent reflexes [3–5]. These symptoms can seriously impair
the patient’s quality of life (QoL) and are thus important to
address.
Colorectal cancer (CRC) is among the leading causes of
cancer-related mortality, and its prevalence has increased in
Japan. Oxaliplatin is a third-generation platinum-based cyto-
toxic agent that is used in the oxaliplatin-based regimen
FOLFOX, a standard chemotherapeutic protocol for the treat-
ment of advanced CRC patients with metastasis and in adju-
vant settings [6]. The safety profile of oxaliplatin, for which
renal or hematologic toxicity is uncommon, is somewhat
different from that of conventional platinum-based com-
pounds [4, 7–9], as the principal and dose-limiting cumulative
toxicity associated with oxaliplatin-based chemotherapy is
neurotoxicity [10].
Two distinct forms of oxaliplatin-induced neuropathy have
been described in the literature. The first is a unique acute,
transient peripheral nerve hyperexcitability syndrome that
occurs shortly after the infusion of oxaliplatin. This form of
neuropathy usually occurs with low total cumulative doses
and can be triggered or exacerbated by exposure to cold
stimuli. Patients might experience paresthesia and dysesthesia
of the hands and feet, as well as of the larynx and jaw. These
symptoms tend to occur within hours of exposure and are
reversible over time, especially over the next few hours and
days. The symptoms do not generally lead to discontinuation
of oxaliplatin-based chemotherapy [10]. Second, a chronic
peripheral sensory neuropathy occurs mainly in distal extrem-
ities and presents with symptoms similar to those of cisplatin-
induced neuropathy. The development of chronic neuropathy
is reported to correlate with the cumulative oxaliplatin dose.
Indeed, a loss of sensation, dysesthesia, and even functional
impairment can develop progressively after several cycles of
oxaliplatin-based therapy. These effects are reversible, but
might last for several months and have had a significant
impact on the continuation of oxaliplatin-based treatment
[11], as these painful symptoms often disrupt the chemother-
apy schedule. Furthermore, patients who are unable to com-
plete a planned therapy program might suffer from chronic
discomfort and a decreased QoL [12–15].
CIPN-related pain is predominantly neuropathic, and
controlled-release (CR) oxycodone was found to be effica-
cious and tolerable for the treatment of neuropathic pain in
several clinical settings. A meta-analysis of the role of opioids
in the treatment of benign neuropathic pain showed that
opioids, particularly oxycodone, were more effective than
other agents [16, 17]. A randomized phase II trial showed that
the combination of oxycodone and pregabalin was effective
and safe for the treatment of neuropathic pain in cancer
patients [18].
The objective of this study was to evaluate the efficacy and
tolerability of oxycodone in oxaliplatin-induced peripheral




We retrospectively reviewed the medical records of patients
with histologically confirmed CRC between November 2006
and February 2012 at the Toho University Sakura Medical
Center (Sakura, Japan). Among the reviewed patients, a total
of 64 advanced CRC patients with stage III or IV disease were
included in this study. All eligible patients underwent gross
resection of the primary CRC (microscopic residual disease or
residual marginal involvement was allowed) and subsequently
received curative-intent oxaliplatin-based FOLFOX therapy.
The key inclusion criteria were as follows: ≥18 years of age, a
World Health Organization (WHO) performance status score
of 0 or 1, and a life expectancy of ≥6 months. Patients with
preexisting peripheral neuropathy or those who were previ-
ously exposed to other neurotoxic chemotherapeutic agents
were excluded from the study.
All patients received modified FOLFOX6 (mFOLFOX6)
therapy. mFOLFOX6 comprises a bolus of 85 mg/m2
oxaliplatin, 250 mg/m2 leucovorin, and 400 mg/m2 5-
fluorouracil (5-FU), followed by a 48-h continuous infusion
of 5-FU at 2500 mg/m2, given every 2 weeks. Bevacizumab,
cetuximab, or panitumumab was administered prior to
mFOLFOX6 in 27 cases. On a case-by-case basis, the physi-
cian in charge determined whether dose reduction or treatment
interruption was appropriate in the instance of a severe toxic-
ity response. Oxaliplatin-based FOLFOX chemotherapy was
continued until disease progression (PD), the decision to use
alternative therapies, unacceptable toxicities, or patient refusal
of further treatment.
Study design
Patients were divided into two groups. Patients with cancer-
related pain who had been administered CR oxycodone during
the FOLFOX therapy period were defined as the OXY group.
Patients who did not receive CR oxycodone treatment were
defined as the non-OXY group. The OXY and non-OXY
groups included 29 and 35 patients, respectively. No opioids
besides CR oxycodone were administered to the study popu-
lation before and during FOLFOX therapy. Regarding other
analgesics, clonazepamwas administered to six patients in the
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OXY group and two patients in the non-OXY group, and
gabapentin was administered to one patient in the non-OXY
group. Neurological toxicities were assessed according to the
Common Terminology Criteria for Advanced Events
(CTCAE) version 3.0 (U.S. Department of Health and Human
Services, National Institutes of Health, National Cancer Insti-
tute). The severity of neurological toxicity was evaluated as
the worst score in each patient during FOLFOX therapy. A
peripheral sensory neuropathy subscale was applied to grade
the clinical severity as follows: grade 1, asymptomatic or with
a loss of deep tendon reflex or paresthesia (including tingling)
that did not interfere with function; grade 2, sensory alter-
ations or paresthesia (including tingling) that interfered with
function, but not with activities of daily living (ADL); and
grade 3, sensory alterations or paresthesia that interfered with
ADL [19]. Pain intensity was also measured on a numeric
rating scale after each cycle of FOLFOX therapy. In this study,
we focused on oxaliplatin-induced chronic cumulative neu-
ropathy because this type of neuropathy might result in severe
neurologic function disturbances and significantly impact the
continuation of oxaliplatin treatment.
Statistical analysis
The study was designed to determine differences between
patients in the OXY and non-OXY groups, undergoing
oxaliplatin-based FOLFOX therapy. For both treatment
groups, the medians and relative frequencies were compared
using Welch’s t-test for two independent samples and the
Wilcoxon signed-rank test and Fisher’s exact test, respective-
ly. Statistical significance was determined as P<0.05.
Results
Baseline characteristics of the eligible patients (Table 1)
The demographic and clinicopathological data collected from
the medical records of 64 patients are shown in Table 1. The
OXY group included 29 patients, and CR oxycodone was
administered to five patients with cancer-related pain before
starting FOLFOX therapy. The daily CR oxycodone doses at
baseline ranged from 10 to 40 mg. Other patients in the OXY
group received CR oxycodone after the occurrence of painful
peripheral neuropathy. The OXY and non-OXY groups did
not significantly differ in age (P=0.2582; Welch’s t-test) or
gender (P=1.0000; Fisher’s exact test). The maximum daily
CR oxycodone doses were as follows: 160 mg for one patient
(3.4 %), 40 mg for two patients (6.9 %), 30 mg for three
patients (10.3 %), 20 mg for three patients (10.3 %), 15mg for
two patients (6.9 %), and 10 mg for 18 patients (62.1 %).
CTCAE grading of sensory neuropathy during the study
period (Table 2)
As shown in Table 2, all patients (100 %) in the OXY group
and 33 patients (94.3 %) in the non-OXY group experienced
grade 1 or 2 sensory neuropathy. Grade 3 neurotoxicity was
not observed in the OXY group, whereas two patients (5.7 %)
in the non-OXY group reported grade 3 sensory neuropathy.
Although 14 patients (40 %) in the non-OXY group reported
mild pain, these patients did not receive opioid therapy. In
contrast, every patient in the OXY group who experienced
more than mild pain received CR oxycodone. In the OXY
group, pain was generally well controlled by adequate dose
titration. Two months after the completion of FOLFOX ther-
apy, the sensory neuropathy worsened from grade 1 to 2 in 1
non-OXY group patient, whereas the sensory neuropathy
grades remained stable or improved in the other group pa-
tients. In the OXY group, the sensory neuropathy grades
improved in every patient. CR oxycodone was discontinued
in ten patients (34.5 %) in the OXY group after the completion
of FOLFOX therapy.
















mFOLFOX + bevacizumab 7 18
mFOLFOX + bevacizumab +
panitumumab
0 2
Table 2 CTCAE grading of sensory neuropathy during study period
Non-OXY group (N=35) OXY group (N=29)
Grade 1 9 4
Grade 2 24 25
Grade 3 2 0
Grade 4 0 0
Grade 5 0 0
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Causes of FOLFOX therapy discontinuation (Table 3)
FOLFOX therapy was interrupted in some cases. The causes
of interruption are listed in Table 3. There were no discontin-
uations due to peripheral neuropathy in the OXY group.
However, for ten patients (28.6 %) in non-OXY group,
FOLFOX therapy was terminated because of severe OIPN.
Eighteen patients (62.1 %) in the OXY group discontinued
FOLFOX therapy because of PD, compared with seven pa-
tients (20 %) in the non-OXY group. Other reasons for
interrupting FOLFOX therapy were unacceptable toxicities
besides peripheral sensory neuropathy, scheduled switching
to alternative therapies, or patient refusal of further treatment.
Frequencies of FOLFOX cycles and total oxaliplatin doses
(Table 4)
We also compared the number of FOLFOX cycles in the OXY
and non-OXY groups. Patients in the OXY group received a
median of 13 cycles of FOLFOX therapy (range, 6–46 cycles).
Patients in the non-OXY group received a median of seven
cycles (range, 2–18 cycles). The number of FOLFOX cycles
in the OXY group significantly exceeded that in the non-OXY
group (P<0.05; Welch’s t-test). The median total oxaliplatin
doses were 1072.3mg/m2 (range, 408.7–3385.3mg/m2) in the
OXY group and 483.0 mg/m2 (range, 76.2–1414.1 mg/m2) in
the non-OXY group. The total administered oxaliplatin dose
was also significantly higher in the OXY group than in the
non-OXY group (P<0.05; Welch’s t-test; Table 4).
There were no statistically significant differences between the
five patients who were administered CR oxycodone before
FOLFOX therapy and the other 24 patients in the OXY group
with regard to the number of FOLFOX cycles (P=0.6094;
Welch’s t-test) and the total oxaliplatin dose (P=0.5424;Welch’s
t-test; data not shown). Therewere also no statistically significant
differences between the OXY group patients who did or did not
receive other analgesics with regard to the number of FOLFOX
cycles (P=0.2503; Welch’s t-test) and the total oxaliplatin dose
(P=0.3186; Welch’s t-test; data not shown).
A total of 15 possible opioid-induced adverse events oc-
curred in ten patients in the OXY group during the FOLFOX
therapy period. Constipation was the most common event and
occurred in eight patients (27.6 %). Other adverse events
included drowsiness (6.7 %), nausea (6.7 %), hallucination
(3.4 %), and anorexia (3.4 %). The severity of each adverse
event was classified as grade 1, and CR oxycodone was not
discontinued in any case because of adverse events.
Discussion
CIPN treatment remains a challenge for clinicians. A number
of protective and treatment approaches that focused on CIPN
were investigated in clinical trials. However, evidence for
pharmacological therapeutic strategies has not been fully
established, and further investigation is required.
Regarding the management of OIPN, current recom-
mendations include patient education, dose modification,
the “s top and go” approach, and the use of
neuromodulatory agents, particularly intravenous calci-
um and magnesium (Ca/Mg) infusion. Ca/Mg infusion
was widely examined, and a meta-analysis that included
four prospective randomized clinical trials and three
retrospective clinical trials suggested that Ca/Mg infu-
sion might decrease the incidence of OIPN without
reducing chemotherapeutic efficacy [20]. However,
Loprinzi et al. revealed that Ca/Mg infusion did not
reduce cumulative OIPN in a recent randomized,
placebo-controlled, double-blind trial [21]. A recent ran-
domized pilot clinical trial also failed to demonstrate a
protective effect of vitamin E on acute OIPN [22].
Several antiepileptic and antidepressant agents, including
amitriptyline, gabapentin, and lamotrigine, did not show
significant efficacy in this setting [23–25]. Among the
serotonin and norepinephrine reuptake inhibitors,
venlafaxine exhibited a therapeutic effect on painful





Progression disease (PD) 7 18
Peripheral neuropathy 10 0
Allergic reaction 6 4
Fever or infection 3 2
Scheduled therapy change 0 3
General debilitation 5 0
Myelosuppression 2 0
Patient’s preference 2 2
Table 4 Frequency of FOLFOX cycles and total oxaliplatin dose
Non-OXY group (N=35) OXY group (N=29)
Median of FOLFOX cycles (range) 7 (2–18) 13 (6–46)*
Median of total oxaliplatin dose (ramge) 483.0 mg/m2 (76.2-1414.1 mg/m2) 1072.3 mg/m2* (408.7-3385.3 mg/m2)
* P<0.05
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OIPN [26]. In addition, duloxetine significantly reduced
CIPN-associated pain intensity in a recent randomized
placebo-controlled crossover trial, suggesting the clinical
efficacy of duloxetine for OIPN [27].
The efficacy and tolerability of opioids for CIPN has rarely
been investigated. However, despite their differing etiologies,
agents used to treat peripheral neuropathic painmight have the
potential to exhibit demonstrable efficacies for CIPN [28].
Given their proven clinical efficacies in treating peripheral
neuropathic pain, opioids might be effective for the treatment
of painful CIPN. In particular, oxycodone provided significant
pain relief from peripheral neuropathic pain caused by post-
herpetic neuralgia or diabetic neuropathy [29–32]. CR oxyco-
done was also shown to be effective for bortezomib-induced
peripheral neuropathic pain in multiple myeloma patients
[33]. Furthermore, recent basic studies have demonstrated that
the antinociceptive effect of oxycodone was superior to that of
morphine in a neuropathic pain mouse model [34] and that the
analgesic profile of oxycodone in a bone cancer pain mouse
model with a neuropathic pain-like state was different from
those of morphine and fentanyl [35]. Although the pharmaco-
logical mechanism of oxycodone against peripheral neuro-
pathic pain remains unclear, the results of those clinical trials
and basic studies suggest that oxycodone could be considered
a therapeutic option for CIPN.
We retrospectively investigated the efficacy and tolerability
of CR oxycodone for OIPN during FOLFOX therapy in CRC
patients. A total of 62.1 % of patients in the OXY group
continued FOLFOX therapy until PD. Conversely, only
20 % of patients in the non-OXY group continued FOLFOX
therapy until PD. The cumulative oxaliplatin dose was signif-
icantly higher in the OXY group than in the non-OXY group.
Because patients in the OXY group received a higher cumu-
lative dose of oxaliplatin, they would be expected to present
with substantially more severe OIPN than patients in the non-
OXY group; however, grade 3 sensory neuropathy only oc-
curred in the non-OXY group. These results suggest that CR
oxycodone might prevent or improve the symptoms of OIPN
in CRC patients.
This study has several limitations. First, the sample
size was small and the study design was observational
and retrospective. Second, the severity of OIPN was
measured according to the CTCAE grading system.
The reliability of the CTCAE scale is controversial,
and a recent study revealed that CTCAE scale
overestimated the occurrence of motor neuropathy [36].
Finally, the pain intensity in 23 patients (79.3 %) in the
OXY group remained mild during the study period, and
thus, it was difficult to evaluate the analgesic effects of
CR oxycodone on OIPN. Therefore, the continuation of
oxaliplatin administration was worth evaluating to con-
firm the therapeutic efficacy and tolerability of CR
oxycodone in patients with OIPN.
Conclusion
In conclusion, we demonstrated that patients who were ad-
ministered CR oxycodone received significantly more cycles
of FOLFOX therapy and a higher cumulative oxaliplatin dose
than did patients who were not administered CR oxycodone.
Although this study had several limitations, the results suggest
that CR oxycodone can attenuate OIPN and extend FOLFOX
therapy in CRC patients.
Acknowledgments This work was supported by Grants-in-Aid from
the Smoking Research Foundation.
Conflict of interest The authors have no conflict of interest to disclose.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any non-
commercial use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited.
References
1. Paice JA (2010) Chronic treatment-related pain in cancer survivors.
Pain 152(3 suppl):S84–S89
2. Malik B, Stillman M (2008) Chemotherapy-induced peripheral neu-
ropathy. Curr Pain Headache Rep 12:165–174
3. Loprinzi CL, Reeves BN,Dakhil SR, Sloan JA,Wolf SL, Burger KN,
Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ,
Lachance DH (2011) Natural history of paclitaxel-associated acute
pain syndrome: prospective cohort study NCCTG N08C1. J Clin
Oncol 29:1472–1478
4. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neu-
rotoxicity pharmacogenetics. Mol Cancer Ther 8:10–16
5. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral
neuropathy. J Neurol 249:9–17
6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J,
Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-
Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med
350:2343–2351
7. Kottschade LA, Sloan JA,MazurczakMA, JohnsonDB,Murphy BP,
Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2011)
The use of vitamin E for the prevention of chemotherapy-induced
peripheral neuropathy: results of a randomized phase III clinical trial.
Support Care Cancer 19:1769–1777
8. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2011)
Allopregnanolone prevents and suppresses oxaliplatin-evoked pain-
ful neuropathy: multi-parametric assessment and direct evidence.
Pain 152:170–181
9. Garg MB, Ackland SP (2011) Pyridoxine to protect from oxaliplatin-
induced neurotoxicity without compromising antitumor effect.
Cancer Chemother Pharmacol 67:963–966
10. Wilson RH, Lehky T, Thomas RR (2002) Acute oxaliplatin-induced
peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774
11. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML,
Kiernan MC (2011) Dose effects of oxaliplatin on persistent and
transient Na+ conductances and the development of neurotoxicity.
PLoS One 6:e18469
12. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van
de Poll-Franse LV, Saif MW, Reardon J (2013) Chemotherapy-
Support Care Cancer (2014) 22:1579–1584 1583
induced neuropathy and its association with quality of life among 2-
to 11-year colorectal cancer survivors: results from the population-
based PROFILES registry. J Clin Oncol 31:2699–2707
13. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013)
Oxaliplatin-induced peripheral neuropathy’s effects on health-related
quality of life of colorectal cancer survivors. Support Care Cancer 21:
3307–3313
14. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K,
Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K,
Watanabe T, Hausheer FH (2012) Taxane-induced peripheral neurop-
athy and health-related quality of life in postoperative breast cancer
patients undergoing adjuvant chemotherapy: N-SAS BC02 A ran-
domized clinical trial. Support Care Cancer 20:3355–3364
15. Tofthagen C (2010) Surviving chemotherapy for colon cancer and
living with the consequences. J Palliat Med 13:1389–1391
16. Eisenberg E, McNicol ED, Carr DB (2005) Efficacy and safety of
opioid agonists in the treatment of neuropathic pain of nonmalignant
origin: systematic review andmeta-analysis of randomized controlled
trials. JAMA 293:3043–3052
17. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids
for chronic noncancer pain: a meta-analysis of effectiveness and side
effects. CMAJ 174:1589–1594
18. GarassinoMC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C,
Febbraro A, Bianchi A, Bramati A,Moretti A, GanzinelliM,Marabese
M, Gentili M, Torri V, Farina G (2013) Randomised phase II trial
(NCT00637975) evaluating activity and toxicity of two different esca-
lating strategies for pregabalin and oxycodone combination therapy for
neuropathic pain in cancer patients. PLoS One 8:e59981
19. U.S. Department of Health and Human Services (2009) Common
terminology criteria of adverse events (CTCAE) version 3.0
20. Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J,
Li Q (2013) Ca/Mg infusions for the prevention of oxaliplatin-related
neurotoxicity in patients with colorectal cancer : a meta-analysis. Ann
Oncol 24:171–178
21. Loprinzi L, Qin R, Dakhil SR, Fehrenbacher K, Stella PJ, Atherton
PJ, Seisler DK, Qamar R, Lewis GC, Grothey A (2013) Phase III
randomized, placebo (PL)-controlled, double-blind study of intrave-
nous calcium/magnesium (CaMg) to prevent oxaliplatin-induced
sensory neurotoxicity (sNT), N08CB : an alliance for clinical trials
in oncology study. J Clin Oncol 31(15 suppl):3501
22. de Afonseca SO, Cruz FM, de Iracema Gomes Cubero D, Lera AT,
Schindler F, Okawara M, de Souza LF, Rogrigues NP, del Giglio A
(2013) Vitamin E for prevention of oxaliplatin-induced peripheral
neuropathy : a pilot randomized clinical trial. Sao Paulo Med J 131:
35–38
23. Kautio A-L, Haanpaa M, Leminen A, Kalso E, Kautiainen H, Saarto
T (2009) Amitriptyline in the prevention of chemotherapy-induced
neuropathic symptoms. Anticancer Res 29:2601–2606
24. Rao RD,Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nickcevich
DA, Warner DO, Novotny P, Kutteh LA, Wong GY, the North
Central Cancer Treatment Group (2007) Efficacy of gabapentin in
the management of chemotherapy-induced peripheral neuropathy : A
phase 3 randomized, double-blind, placebo-controlled, crossover trial
(N00C3). Cancer 110:2110–2118
25. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB,
Gross HM, Nashawaty M, Loprinzi CL (2008) Efficacy of
lamotrigine in the management of chemotherapy-induced peripheral
neuropathy : A phase 3 randomized, double-blind, placebo-
controlled trial, N01C3. Cancer 112:2802–2808
26. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O,
Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y,
Goldwasser F (2012) Efficacy of venlafaxine for the prevention and
relief of oxaliplatin-induced acute neurotoxicity : results of EFFOX, a
randomized, double-blind, placebo-controlled phase III trial. Ann
Oncol 23:200–205
27. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T,
Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB,
Shapiro CL (2013) Effect of duloxetine on pain, function, and quality
of life among patients with chemotherapy-induced painful peripheral
neuropathy: a randomized clinical trial. JAMA 309:1359–1367
28. Urch CE, Dickenson AH (2008) Neuropathic pain in cancer. Eur J
Pain 44:1091–1096
29. Watson CPN, Babul N (1998) Efficacy of oxycodone in neuropathic
pain: a randomized trial in postherpetic neuralgia. Neurology 50:
1837–1841
30. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J
(2003) Controlled-release oxycodone relieves neuropathic pain: a
randomized controlled trial in painful diabetic neuropathy. Pain
105:71–78
31. Gimbel JS, Rochards P, Portenoy RK (2003) Controlled-release
oxycodone for pain in diabetic neuropathy: a randomized controlled
trial. Neurology 60:927–934
32. Hanna M, O’Brien C, Wilson MC (2008) Prolonged-release oxyco-
done enhances the effects of existing gabapentin therapy in painful
diabetic neuropathy patients. Eur J Pain 12:804–813
33. Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S,
Tendas A, Scaramucci L, Cupelli L, D’Elia GM, Truini A, Niscola
P, Petrucci MT (2012) Controlled-release oxycodone for the treat-
ment of bortezomib-induced neuropathic pain in patients with mul-
tiple myeloma? Support Care Cancer 20:2621–2626
34. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M,
Suzuki T (2008) Comparative pharmacological profiles of morphine
and oxycodone under a neuropathic pain-like state in mice: evidence
for less sensitivity to morphine. Neuropsychopharmacology 33:
1097–1112
35. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto
M, Orita S, Matsushima S, Miyoshi T, Masuno K, Torii M, Koike K,
Shimada S, Kanemasa T, Kihara T, Narita M, Suzuki T, Kato A
(2009) Morphine, oxycodone, and fentanyl exhibit different analge-
sic profiles in mouse pain models. J Pharmacol Sci 111:60–72
36. Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi
M, Ildebrando M, Cavaaletti G (2011) Chemotherapy-induced pe-
ripheral neurotoxicity can be misdiagnosed by the National Cancer
Institute Common Toxicity scale. J Peripher Nerv Syst 16:228–236
1584 Support Care Cancer (2014) 22:1579–1584
